We are live on ! Find out more
MBOT icon

Microbot Medical

70 hedge funds and large institutions have $22.8M invested in Microbot Medical in 2025 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 15 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $1.94M | Put options by funds: $991K

46% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 13

13% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 15

4% more funds holding

Funds holding: 6770 (+3)

0.02% less ownership

Funds ownership: 16.98%16.96% (-0.02%)

17% less capital invested

Capital invested by funds: $27.4M → $22.8M (-$4.58M)

Holders
70
Holders Change
+3
Holders Change %
+4.48%
% of All Funds
0.85%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
17
Reduced
15
Closed
13
Calls
$1.94M
Puts
$991K
Net Calls
+$950K
Net Calls Change
-$1.44M
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$6.66M +$2.34M +986,160 +42%
CIBC Private Wealth Group
2
CIBC Private Wealth Group
Georgia
$2.96M +$61.6K +26,000 +2%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$2.49M -$11.6K -4,902 -0.4%
BlackRock
4
BlackRock
New York
$1.74M +$897K +378,463 +77%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$1.52M +$636K +268,609 +54%
DnB Asset Management
6
DnB Asset Management
Norway
$1.35M +$1.03M +433,869 +178%
UBS Group
7
UBS Group
Switzerland
$890K +$574K +242,287 +119%
Stifel Financial
8
Stifel Financial
Missouri
$532K +$257K +108,498 +69%
6CM
9
683 Capital Management
New York
$512K +$606K +256,033 New
State Street
10
State Street
Massachusetts
$414K -$3.08K -1,300 -0.6%
AA
11
AlphaCentric Advisors
Puerto Rico
$400K +$474K +200,000 New
Jane Street
12
Jane Street
New York
$395K +$8.92K +3,765 +2%
OAC
13
OMERS Administration Corp
Ontario, Canada
$292K +$346K +146,000 New
Qube Research & Technologies (QRT)
14
Qube Research & Technologies (QRT)
United Kingdom
$263K +$312K +131,696 New
Northern Trust
15
Northern Trust
Illinois
$228K +$80.8K +34,099 +43%
BCM
16
Bridgeway Capital Management
Texas
$222K +$263K +111,000 New
Simplex Trading
17
Simplex Trading
Illinois
$142K +$121K +51,138 +255%
Morgan Stanley
18
Morgan Stanley
New York
$138K +$145K +61,129 +779%
Two Sigma Investments
19
Two Sigma Investments
New York
$122K -$3.09K -1,303 -2%
Barclays
20
Barclays
United Kingdom
$119K +$141K +59,376 +5,937,600%
VF
21
Virtu Financial
New York
$117K +$139K +58,674 New
LPL Financial
22
LPL Financial
California
$95.9K -$4.67K -1,973 -4%
Millennium Management
23
Millennium Management
New York
$93.6K -$90K -37,977 -45%
LIP
24
Lighthouse Investment Partners
Florida
$82.2K +$97.4K +41,100 New
HH
25
Hilltop Holdings
Texas
$71.5K

MBOT Hedge Fund Activity: Q4 2025 in Review

70 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Microbot Medical (MBOT) for Q4 2025, worth a combined $22.8M — down 17% from $27.4M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new MBOT positions and 13 closed out — a net gain of 6 holders — while 17 added to existing stakes and 15 trimmed.

The largest buyer was Vanguard Group, adding an estimated $2.34M. The largest seller was Heights Capital Management, exiting entirely with an estimated $2.69M sold.

  • 70 institutional investors held Microbot Medical (MBOT) as of Q4 2025, up from 67 in Q3 2025.
  • Funds reported $22.8M of Microbot Medical stock for Q4 2025, down 17% quarter-over-quarter.
  • 19 funds opened new Microbot Medical positions in Q4 2025 and 13 closed out, a net change of +6 holders.
  • The largest Microbot Medical buyer in Q4 2025 was Vanguard Group, an estimated $2.34M added.
  • The largest Microbot Medical seller in Q4 2025 was Heights Capital Management, an estimated $2.69M sold.

Based on aggregated 13F filings for Q4 2025.